Search
Trastuzumab per al tractament del càncer gàstric o d'unió gastroesofàgica metàstasic HER2+: informe d'avaluació de resultats
(2018)
Trastuzumab is a humanized monoclonal antibody against human epidermal growth factor (HER2) receptor 2, which in 2010 was approved by the European Agency of the
Medication (EMA) for the treatment of gastric cancer or ...
Tractament del CPNM metastàtic EFGR positiu amb inhibidors d’ITK en primera línia: informe d'avaluació de resultats
(2021)
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of new cases of LC for 2019 was 29,503 cases. LC remains the leading cause of cancer death in Spain in both ...
Durvalumab per al tractament del càncer de pulmó no microcític estadi III irresecable
(2020-03-25)
Non-microcytic lung cancer (CPNM) in stage III consists of a heterogeneous population with two subsets: stage IIIA and IIIB. Most patients with stage IIIA / B have an inoperable (non-resectable) disease. Only a third of ...
Tractament del CPNM metastàtic en primera i segona línia amb immunoteràpia: informe d'avaluació de resultats
(2021)
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of LC for 2019 was 29,503 new cases. LC remains the leading cause of cancer death in Spain in both sexes, with ...
Atezolizumab per al tractament del carcinoma urotelial localment avançat o metastàtic
(2018-10-18)
Urothelial carcinoma (CU) of urinary tract, also known as cell carcinoma transitional of the urinary tract, represents around 85-95% of all the cancers of the urinary tract. The term urothelial refers to the epithelium ...
Pertuzumab en combinació amb trastuzumab i quimioteràpia per al tractament neoadjuvant de pacients adults amb càncer de mama HER2 positiu, localment avançat, inflamatori, o en estadi precoç amb alt risc de recaiguda: informe d'avaluació de resultats
(2020)
Breast cancer (BC) is the most common neoplasm in women and the leading cause of cancer death in European women. Pertuzumab is a monoclonal antibody that inhibits epidermal growth factor (HER2) receptor 2 dimerization. The ...